Update on Pharmacologic Options for Smoking Cessation Treatment

American Journal of Medicine

Volumn 121, Issue 4 SUPPL., 2008, Pages

  Nides, Mitchell ^a  

^a Los Angeles Clinical Trials   (United States)

Author keywords

Antidepressants; Clonidine; Nicotine replacement; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; CHOLERA TOXIN B SUBUNIT; CLONIDINE; NICOTINE; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; NOSE SPRAY; RIMONABANT; VARENICLINE;

ABNORMAL DREAMING; ANXIETY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROENTERITIS; HEADACHE; HUMAN; INFLUENZA; INHALER; INSOMNIA; LOZENGE; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESTLESSNESS; RHINOPHARYNGITIS; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; TREMOR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DRUG ADMINISTRATION ROUTES; HUMANS; NICOTINE; SMOKING; SMOKING CESSATION;

EID: 40749147526     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.01.016     Document Type: Article

References (82)

1. Guide to Quitting Smoking (2006), American Cancer Society, Atlanta, GA
2. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2000. MMWR Morb Mortal Wkly Rep 51 (2002) 642-645
3. Centers for Disease Control and Prevention. Cigarette smoking among adults-United States, 2004. MMWR Morb Mortal Wkly Rep 54 (2005) 1121-1124
4. Hughes J.R., Keely J., and Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99 (2004) 29-38
5. Shiffman S., Gnys M., Richards T.J., Paty J.A., Hickcox M., and Kassel J.D. Temptations to smoke after quitting: a comparison of lapsers and maintainers. Health Psychol (1996) 455-461
6. Shiffman S., and Waters A.J. Negative affect and smoking lapses: a prospective analysis. J Consult Clin Psychol 72 (2004) 192-201
7. Hughes J.R., and Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43 (1986) 289-294
8. Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (2000), American Psychiatric Association, Washington, DC
9. Cummings K.M., Giovino G., Jaen C.R., and Emrich L.J. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav 10 (1985) 373-381
10. Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD: US Dept of Health and Human Services, Public Health Service (in press).
11. Henningfield J.E., Fant R.V., Buchhalter A.R., and Stitzer M.L. Pharmacotherapy for nicotine dependence. CA Cancer J Clin 55 (2005) 281-299
12. Nides M. Optimizing nicotine replacement therapy: patient matching and patient choice. Presented at the National Cancer Institute's Tobacco Control Investigators Meeting; June 2, 2004; San Diego, California.
13. Schneider N.G., Terrace S., Koury M.A., et al. Comparison of three nicotine treatments: initial reactions and preferences with guided use. Psychopharmacology (Berl) 182 (2005) 545-550
14. Schneider N.G., Olmstead R.E., Nides M., et al. Comparative testing of 5 nicotine systems: initial use and preferences. Am J Health Behav 28 (2004) 72-86
15. Gross J., and Stitzer M.L. Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacology (Berl) 98 (1989) 334-341
16. Foulds J., Burke M., Steinberg M., et al. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 9 (2004) 39-53
17. Benowitz N.L. Nicotine replacement therapy: what has been accomplished-can we do better?. Drugs 45 (1993) 157-170
18. Benowitz N.L., Porchet H., Sheiner L., and Jacob III P. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 44 (1988) 23-28
19. Johansson C.J., Olsson P., Bende M., et al. Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 41 (1991) 585-588
20. Henningfield J.E. Nicotine medications for smoking cessation. N Engl J Med 333 (1995) 1196-1203
21. Silagy C., Lancaster T., Stead L., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3 (2004) CD000146
22. Hajek P., West R., Foulds J., et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 159 (1999) 2033-2038
23. Cepeda-Benito A., Reynoso J.T., and Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 72 (2004) 712-722
24. Joseph A.M., Norman S.M., Ferry L.H., et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335 (1996) 1792-1798
25. Hubbard R., Lewis S., Smith C., et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tob Control 14 (2005) 416-421
26. West R., Hajek P., Foulds J., et al. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 149 (2000) 198-202
27. Zyban (bupropion hydrochloride) sustained-release tablets [prescribing information] (2005), GlaxoSmithKline, Research Triangle Park, NC
28. Fryer J.D., and Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288 (1999) 88-92
29. Cryan J.F., Bruijnzeel A.W., Skjei K.L., and Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 168 (2003) 347-358
30. Lerman C., Roth D., Kaufmann V., et al. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67 (2002) 219-223
31. Hughes J.R., Stead L.F., and Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 4 (2004) CD000031
32. Jorenby D. Clinical efficacy of bupropion in the management of smoking cessation. Drugs 62 suppl 2 (2002) 25-35
33. Gonzales D., Bjornson W., Durcan M.J., et al. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med 22 (2002) 234-239
34. Nides M., Rand C., Dolce J., et al. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol 13 (1994) 354-361
35. Doherty K., Militello F.S., Kinnunen T., and Garvey A.J. Nicotine gum dose and weight gain after smoking cessation. J Consult Clin Psychol 64 (1996) 799-807
36. Hays J.T., Hurt R.D., Rigotti N.A., et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 135 (2001) 423-433
37. Dunner D.L., Zisook S., Billow A.A., et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 59 (1998) 366-373
38. Boshier A., Wilton L.V., and Shakir S.A. Evaluation of the safety of bupropion (Zyban 3) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 59 (2003) 767-773
39. Tonstad S., Farsang C., Klaene G., et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 24 (2003) 946-955
40. Chantix (varenicline) [prescribing information] (2006), Pfizer Inc, New York
41. 2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48 (2005) 3474-3477
42. 2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 (2007) 985-994
43. 2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
44. 4* receptors: sufficient for reward, tolerance, and sensitization. Science 306 (2004) 1029-1032
45. 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 47-55
46. 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296 (2006) 56-63
47. 2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 29 (2007) 1027-1039
48. 2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 29 (2007) 1040-1056
49. Tonstad S., Tonnesen P., Hajek P., et al. Effect of maintenance therapy with varenicline for smoking cessation. JAMA 296 (2006) 64-71
50. Hays J.T., Ebbert J.O., and Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med 121 4A (2008) S32-S42
51. Ohlsen R.I., and Pilowsky L.S. The place of partial agonism in psychiatry: recent developments. J Psychopharmacol 19 (2005) 408-413
52. Hughes J.R., Stead L.F., and Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res 7 (2005) 491-499
53. Pamelor (nortriptyline HCl) [prescribing information] (2006), Mallinckrodt, Inc, St. Louis, MO
54. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 2nd ed (2000), American Psychiatric Association, Arlington, VA
55. Hall S.M., Reus V.I., Munoz R.F., et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55 (1998) 683-690
56. Catapres (clonidine hydrochloride USP) [prescribing information]. Ridgefield, CTBoehringer Ingelheim (1998)
57. Catapres transdermal therapeutic system [prescribing information]. Ridgefield, CTBoehringer Ingelheim (2006)
58. 2 Adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2 (2003) CD002024
59. Gourlay S.G., and Benowitz N.L. Is clonidine an effective smoking cessation therapy?. Drugs 50 (1995) 197-207
60. Gourlay S.G., Stead L.F., and Benowitz N.L. Clonidine for smoking cessation. Cochrane Database Syst Rev 3 (2004) CD000058
61. Jorenby D.E., Leischow S.J., Nides M.A., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (1999) 685-691
62. Steinberg M.B., Foulds J., Richardson D.L., et al. Pharmacotherapy and smoking cessation at a tobacco dependence clinic. Prev Med 42 (2006) 114-119
63. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
64. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav 81 (2005) 387-395
65. Sanofi-aventis received from the FDA an approvable letter for rimonabant for weight management and a non approvable letter for smoking cessation. [press release]. Paris: sanofi-aventis; February 17, 2006. http://en.sanofi-aventis.com/press/ppc_12724.asp#3 Accessed October 19, 2007
66. Klesges R.C., Winders S.E., Meyers A.W., et al. How much weight gain occurs following smoking cessation?. A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol 65 (1997) 286-291
67. Fagerström K., and Balfour D.J. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 15 (2006) 107-116
68. Rimonabant regulatory update in the United States. Paris: sanofi-aventis; June 29, 2007. http://en.sanofi-aventis.com/press/ppc_18223.asp Accessed October 19, 2007
69. CHMP approves labelling update of Acomplia in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depression. [press release]. Paris: sanofi-aventis; July 19, 2007. http://en.sanofi-aventis.com/press/ppc_18633.asp#3 Accessed October 22, 2007
70. 1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 13 (2002) 451-463
71. 1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 30 (2005) 145-155
72. Reynolds J., and Campbell R.K. Emerging treatment for diabetes, obesity, and smoking. US Pharmacist 11 (2005) 75-79. http://www.uspharmacist.com/index.asp?show=article&page=8_1627.htm Available at: http://www.uspharmacist.com/index.asp?show=article&page=8_1627.htm. Accessed July 18, 2007
73. Acomplia (rimonabant). [Summary of Product Characteristics document]. Paris: sanofi-aventis; August 31, 2007. http://www.sanofi-aventis.co.uk/products/Acomplia_SPC.pdf Accessed January 20, 2008
74. Hatsukami D.K., Rennard S., Jorenby D., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78 (2005) 456-467
75. Pentel P.R., Malin D.H., Ennifar S., et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65 (2000) 191-198
76. de Villiers S.H., Lindblom N., Kalayanov G., et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 69 (2002) 247-253
77. Lesage M.G., Keyler D.E., Hieda Y., et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (Berl) 184 (2006) 409-416
78. Lindblom N., de Villiers S.H., Kalayanov G., et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 69 (2002) 254-260
79. Vaccine to treat nicotine addiction promotes 12 months continuous abstinence in subjects who achieve high antibody levels [press release] (2005), Cytos Biotechnology, Zurichy
80. Anti-smoking vaccine TA-NIC preliminary 12 month clinical trial results [press release] (2005), Xenova Group, Berkshire, United Kingdom
81. Nabi Biopharmaceuticals initiates phase IIB "proof-of-concept" study for NicVAX [press release] (2006), Nabi Biopharmaceuticals, Boca Raton, FL
82. Niaura R. Nonpharmacologic therapy for smoking cessation: characteristics and efficacy of current approaches. Am J Med 121 4A (2008) S11-S19